Literature DB >> 276417

Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemia.

O B Eden, W Goldie, T Wood, E Etcubanas.   

Abstract

Two young children (3 1/2 years and 19 months) developed seizures within 24 hours of receiving intrathecal cytosine arabinoside. Both had previously received intrathecal cytosine and methotrexate as well as cranial irradiation without untoward effect. Possible mechanisms of causation are discussed and caution is stressed for use of intrathecal cytosine arabinoside in young children.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 276417     DOI： 10.1002/1097-0142(197807)42:1<53::aid-cncr2820420108>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  6 in total

Review 1.  Intrathecal chemotherapy with antineoplastic agents in children.

Authors:  A Ruggiero; V Conter; M Milani; E Biagi; I Lazzareschi; P Sparano; R Riccardi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 3.  Pharmacologic strategies for the treatment of meningeal malignancy.

Authors:  S M Blaney; D G Poplack
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 4.  Current pharmacological treatment approaches to central nervous system leukaemia.

Authors:  S M Blaney; F M Balis; D G Poplack
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

5.  Exchange of cerebrospinal fluid in accidental intrathecal overdose of cytarabine.

Authors:  P Lafolie; J Liliemark; O Björk; J Aman; L Wranne; C Peterson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

Review 6.  Toxicity of treatment for neoplastic meningitis.

Authors:  Tali Siegal
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.